Press release
SGLT-2 Inhibitors Market to Reach USD 32.16 Billion by 2033 | Cardiorenal Indications, Generics & Expanding Diabetes Burden Drive 7.1% CAGR
SGLT-2 Inhibitors Market
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-
https://www.datamintelligence.com/download-sample/sglt-2-inhibitors-market?sindhuri
North America: Key Industry Developments (Largest Region)
✅ November 2025: Boehringer Ingelheim and Eli Lilly advanced Jardiance expansions with new data reinforcing cardiorenal protection in broader patient populations, driving prescription growth in the U.S.
✅ October 2025: AstraZeneca's Farxiga gained further traction with pediatric extensions and cost-accessibility programs amid high diabetes prevalence.
✅ September 2025: U.S. HHS initiatives and guideline updates positioned SGLT-2 inhibitors as preferred therapies for comorbid conditions, boosting hospital and retail adoption.
Asia Pacific: Key Industry Developments (Fastest Growing Region)
✅ November 2025: Glenmark, Alkem, and Mankind Pharma expanded generic empagliflozin offerings in India, enhancing affordability for rising type 2 diabetes cases.
✅ October 2025: Mitsubishi Tanabe launched innovative combination therapies in Japan, aligning with national diabetes management programs.
✅ September 2025: Regional governments in China and India subsidized screenings and treatments, accelerating SGLT-2 adoption amid surging CKD and obesity burdens.
Key Mergers and Acquisitions :
✅ Lupin acquires Boehringer trademarks: In late 2024/early 2025, Lupin acquired key anti-diabetes brands from Boehringer Ingelheim to strengthen its SGLT-2 portfolio in emerging markets.
✅ Strategic partnerships for generics: Multiple Indian pharma firms launched empagliflozin generics, intensifying competition and access in high-growth regions.
Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=sglt-2-inhibitors-market?sindhuri
(Purchase 2 or more Reports and get 50% Discount)
Market Segmentation Analysis:
-By Drug: Empagliflozin Leads with Dominant Share
The Empagliflozin segment (Jardiance) commands the largest market share (~50.77% in 2024), driven by strong clinical evidence in cardiorenal protection and broad indications.
Dapagliflozin and emerging generics are fastest-growing amid affordability pushes.
-By Indication: Type-2 Diabetes Commands Largest Portion
Type-2 Diabetes remains dominant, but Chronic Kidney Disease (CKD) is the fastest-growing due to recent approvals and evidence in non-diabetic patients.
-By Distribution Channel: Hospital Pharmacies Top with Strong Demand
Hospital Pharmacies lead for complex comorbid cases, while Retail and Online grow rapidly with generics.
Growth Drivers:
Rising Prevalence of Type 2 Diabetes and Obesity - Global cases projected to surge, necessitating advanced therapies.
Expanding Cardiorenal Indications - Proven benefits in CKD and heart failure broaden patient pools.
Regulatory Approvals and Guideline Updates - Pediatric extensions and first-line recommendations accelerate adoption.
Generic Launches and Cost Accessibility - Increasing affordability in emerging markets.
Strong Clinical Evidence and R&D - Ongoing trials for combinations and new indications.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/sglt-2-inhibitors-market?sindhuri
Regional Insights:
North America dominates the global SGLT-2 Inhibitors market, accounting for the largest share (41.9% in 2024). This leadership is due to high prevalence of diabetes/CKD/heart failure, early regulatory approvals, premium pricing, robust reimbursement, and presence of innovators driving novel therapies.
Asia-Pacific is the fastest-growing region (CAGR ~19.0%), fueled by massive diabetes burden, government initiatives, generic launches, and improving healthcare access in populous nations.
Key Players:
Eli Lilly and Company | Boehringer Ingelheim International GmbH | AstraZeneca | Johnson & Johnson Services, Inc. | Pfizer Inc. | Merck & Co., Inc. | TheracosBio, LLC | Lexicon Pharmaceuticals, Inc.
Key Highlights (Top 5 Key Players) for SGLT-2 Inhibitors Market:
1. Eli Lilly and Company (with Boehringer Ingelheim) maintains leadership via Jardiance (empagliflozin), dominating with superior cardiorenal outcomes and expanding indications.
2. AstraZeneca excels with Farxiga (dapagliflozin), strong in CKD and pediatric approvals for broader accessibility.
3. Johnson & Johnson differentiates through Invokana (canagliflozin), focusing on established glycemic and renal benefits.
4. Pfizer Inc. supports market with ertugliflozin partnerships, targeting combination therapies.
5. Merck & Co., Inc. advances through sotagliflozin (dual inhibitor) for heart failure-focused differentiation.
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sindhu
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release SGLT-2 Inhibitors Market to Reach USD 32.16 Billion by 2033 | Cardiorenal Indications, Generics & Expanding Diabetes Burden Drive 7.1% CAGR here
News-ID: 4314573 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Automotive Battery Market to Hit USD 100 Billion by 2031 | Driven by EVs, Hybrid …
Global Automotive Battery Market reached USD 65.2 billion in 2022 and is expected to reach USD 100.0 billion by 2031, growing with a CAGR of 5.5% during the forecast period 2024-2031.
Automotive Battery refers to a rechargeable or non-rechargeable energy storage device used to power vehicle electrical systems and enable engine starting or propulsion. In conventional vehicles, lead-acid batteries support ignition, lighting, and onboard electronics. In electric and hybrid vehicles, advanced…
Biopharmaceutical Tubing Market Expected to Reach US$ 8.65 Billion by 2033 Drive …
The global biopharmaceutical tubing market reached US$ 4.15 Billion in 2024 and is expected to reach US$ 8.65 Billion by 2033, growing at a CAGR of 8.6% during the forecast period 2025-2033.
The biopharmaceutical tubing market covers specialized polymer and elastomer tubing used in bioprocessing, drug manufacturing, and sterile fluid transfer. These tubes are designed to meet strict regulatory standards for purity, chemical resistance, and biocompatibility. They are critical in applications…
Short Bowel Syndrome Market to Hit $7.93 Billion by 2033 | Driven by Crohn's Dis …
According to DataM Intelligence, the short bowel syndrome market was valued at US$ 1.39 Billion in 2023, grew to US$ 1.64 Billion in 2024, and is expected to reach US$ 7.93 Billion by 2033, expanding at a strong CAGR of 19.3% during 2025-2033. Growth is primarily fueled by the rising prevalence of gastrointestinal disorders such as Crohn's disease, increasing surgical resections, and innovations in GLP-2 analogs that reduce dependence on…
Krill Oil Supplements Market Expected to Reach US$ 1.48 Billion by 2031, Driven …
Global Krill Oil Supplements Market reached US$ 834.11 million in 2023 and is expected to reach US$ 1476.58 billion by 2031, growing with a CAGR of 7.4% during the forecast period 2024-2031.
According to DataM Intelligence has published a new research report on "Krill Oil Supplements Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key…
More Releases for Inhibitors
Thymidine Phosphorylase Inhibitors Market - Breaking the Cycle: Angiogenesis Inh …
Newark, New Castle, USA: The "Thymidine Phosphorylase Inhibitors Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Thymidine Phosphorylase Inhibitors Market: https://www.growthplusreports.com/report/thymidine-phosphorylase-inhibitors-market/8826
This latest report researches the industry structure,…
CGRP Inhibitors Market - Break Free from Migraine: CGRP Inhibitors Redefining Re …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global CGRP Inhibitors Market.
CGRP Inhibitors Market: https://www.growthplusreports.com/report/cgrp-inhibitors-market/9155
The CGRP Inhibitors Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production strategy.…
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
Crude Oil Flow Improvers Market by Type (Paraffin Inhibitors, Asphaltene Inhibit …
Global Crude Oil Flow Improvers Market was valued at $1,282 million in 2016, and is anticipated to reach $1,920 million, growing at a CAGR of 5.7% from 2017 to 2023. Crude oil is one of the most actively traded commodities with a stable growth rate globally. It is extracted from remote locations and needs to be transported through pipelines. Transportation of crude oil via pipeline is relatively difficult, owing to…
Immune Check Point Inhibitors Market Immune Check Point Inhibitors Clinical Pipe …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy
1.1 Overview
1.2 History- From Tragedy to Breakthrough
Major Immune Checkpoints Proteins
2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development
2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development
Mechanism of Action of Immune Checkpoint Inhibitors
3.1 Cytotoxic T lymphocyte Antigen-4…
Global Immune Check Point Inhibitors Market & Immune Check Point Inhibitors Clin …
Immunotherapy represents a paradigm shift in oncology therapy along the multiple fronts. Although, targeted therapy upgrades the underlying signaling defect which results in oncogenesis within the tumor. The immune checkpoint blockade is fundamentally a therapy which directed at the patient's native immune system to tilt the immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing antitumor immunity.
The immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab…
